William Blair Issues Optimistic Forecast for ELAN Earnings

Elanco Animal Health Incorporated (NYSE:ELAN) – Research analysts at William Blair raised their Q1 2025 earnings per share estimates for shares of Elanco Animal Health in a research report issued on Tuesday, February 25th. William Blair analyst B. Vazquez now expects that the company will earn $0.32 per share for the quarter, up from their previous estimate of $0.30. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share.

Several other brokerages have also weighed in on ELAN. Stifel Nicolaus reduced their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Leerink Partners started coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price target on the stock. Barclays dropped their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Finally, UBS Group reduced their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Elanco Animal Health has an average rating of “Hold” and an average target price of $15.83.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $10.93 on Friday. Elanco Animal Health has a 1 year low of $10.20 and a 1 year high of $18.80. The company’s 50-day moving average is $11.72 and its two-hundred day moving average is $13.05. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The company has a market cap of $5.40 billion, a PE ratio of 27.31, a PEG ratio of 2.50 and a beta of 1.42.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company’s revenue was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.08 EPS.

Hedge Funds Weigh In On Elanco Animal Health

Large investors have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of Elanco Animal Health by 1,153.6% in the fourth quarter. FMR LLC now owns 40,232,327 shares of the company’s stock valued at $487,213,000 after purchasing an additional 37,022,891 shares in the last quarter. JPMorgan Chase & Co. raised its position in Elanco Animal Health by 76.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock valued at $147,747,000 after buying an additional 4,361,799 shares during the last quarter. Norges Bank bought a new stake in Elanco Animal Health in the 4th quarter valued at approximately $47,424,000. Brandes Investment Partners LP boosted its position in Elanco Animal Health by 66.9% during the 4th quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company’s stock worth $69,405,000 after acquiring an additional 2,296,691 shares during the last quarter. Finally, Freestone Grove Partners LP acquired a new position in Elanco Animal Health during the 4th quarter worth approximately $20,396,000. Institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.